The TNK2 antibody targets the non-receptor tyrosine kinase TNK2 (also known as ACK1 or Activated Cdc42-associated kinase 1), a protein involved in diverse cellular signaling pathways. TNK2 regulates key processes such as cell proliferation, survival, migration, and cytoskeletal reorganization by interacting with receptors like EGFR, HER2. and MET. It activates downstream effectors, including the PI3K/AKT and RAS-MAPK pathways, and modulates transcription factors such as AR and WWOX, linking it to cancer progression and therapy resistance.
TNK2 overexpression or hyperactivity is implicated in several cancers, including prostate, breast, and lung cancers, where it correlates with poor prognosis and drug resistance. In neurological contexts, TNK2 interacts with synaptic proteins, suggesting roles in neurodegenerative and neurodevelopmental disorders. TNK2 antibodies are critical tools for research, enabling the detection of TNK2 expression, phosphorylation status, and localization in tissues or cell lines. They aid in studying TNK2's mechanistic roles in disease and its potential as a therapeutic target.
Recent studies explore TNK2 inhibitors and antibodies for cancer treatment, with some in preclinical or early clinical trials. Additionally, TNK2 antibodies may serve as diagnostic or prognostic biomarkers in oncology. Despite progress, challenges remain in understanding TNK2's context-dependent functions and optimizing antibody specificity for clinical applications. Ongoing research aims to clarify its dual roles in promoting or suppressing tumors, depending on cellular context.